Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of PULM opened at $6.29 on Friday. The firm has a market capitalization of $22.97 million, a price-to-earnings ratio of -2.38 and a beta of 1.52. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $8.44. The company has a 50-day moving average of $5.28 and a 200 day moving average of $3.21.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.